AVA7100
Not disclosed
PreclinicalThird Gen pre|CISION® FAP Affimer® Drug Conjugate
Key Facts
Indication
Not disclosed
Phase
Preclinical
Status
Third Gen pre|CISION® FAP Affimer® Drug Conjugate
Company
About Avacta Group
Avacta Therapeutics is challenging conventional cancer drug delivery with its proprietary pre|CISION® platform, which aims to widen the therapeutic index of potent oncology drugs by ensuring release occurs specifically in the tumor microenvironment. The company's lead asset, faridoxorubicin (AVA6000), has demonstrated improved safety and tumor-specific drug concentration in Phase 1 trials, while its second program, AVA6103, incorporates a sustained-release mechanism. Avacta is advancing a pipeline of peptide and Affimer® drug conjugates, with a vision to expand the utility of existing cancer therapies across approximately 90% of solid tumors.
View full company profileTherapeutic Areas
Other Not disclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Multiple Preclinical Programs | Generate Biomedicines | Preclinical |
| Platform Collaboration Programs (Jan 2022) | Generate Biomedicines | Discovery/Preclinical |
| Platform Collaboration Programs (Sep 2024) | Generate Biomedicines | Discovery/Preclinical |